Literature DB >> 15927975

Development of occlusive neointimal lesions in distal pulmonary arteries of endothelin B receptor-deficient rats: a new model of severe pulmonary arterial hypertension.

D Dunbar Ivy1, Ivan F McMurtry, Kelley Colvin, Masatoshi Imamura, Masahiko Oka, Dong-Seok Lee, Sarah Gebb, Peter Lloyd Jones.   

Abstract

BACKGROUND: Human pulmonary arterial hypertension (PAH) is characterized by proliferation of vascular smooth muscle and, in its more severe form, by the development of occlusive neointimal lesions. However, few animal models of pulmonary neointimal proliferation exist, thereby limiting a complete understanding of the pathobiology of PAH. Recent studies of the endothelin (ET) system demonstrate that deficiency of the ET(B) receptor predisposes adult rats to acute and chronic hypoxic PAH, yet these animals fail to develop neointimal lesions. Herein, we determined and thereafter showed that exposure of ET(B) receptor-deficient rats to the endothelial toxin monocrotaline (MCT) leads to the development of neointimal lesions that share hallmarks of human PAH. METHODS AND
RESULTS: The pulmonary hemodynamic and morphometric effects of 60 mg/kg MCT in control (MCT(+/+)) and ET(B) receptor-deficient (MCT(sl/sl)) rats at 6 weeks of age were assessed. MCT(sl/sl) rats developed more severe PAH, characterized by elevated pulmonary artery pressure, diminished cardiac output, and right ventricular hypertrophy. In MCT(sl/sl) rats, morphometric evaluation revealed the presence of neointimal lesions within small distal pulmonary arteries, increased medial wall thickness, and decreased arterial-to-alveolar ratio. In keeping with this, barium angiography revealed diminished distal pulmonary vasculature of MCT(sl/sl) rat lungs. Cells within neointimal lesions expressed smooth muscle and endothelial cell markers. Moreover, cells within neointimal lesions exhibited increased levels of proliferation and were located in a tissue microenvironment enriched with vascular endothelial growth factor, tenascin-C, and activated matrix metalloproteinase-9, factors already implicated in human PAH. Finally, assessment of steady state mRNA showed that whereas expression of ET(B) receptors was decreased in MCT(sl/sl) rat lungs, ET(A) receptor expression increased.
CONCLUSIONS: Deficiency of the ET(B) receptor markedly accelerates the progression of PAH in rats treated with MCT and enhances the appearance of cellular and molecular markers associated with the pathobiology of PAH. Collectively, these results suggest an overall antiproliferative effect of the ET(B) receptor in pulmonary vascular homeostasis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15927975      PMCID: PMC1934986          DOI: 10.1161/CIRCULATIONAHA.104.491456

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  40 in total

1.  An endothelin receptor (ETA) antagonist isolated from Streptomyces misakiensis.

Authors:  M Ihara; T Fukuroda; T Saeki; M Nishikibe; K Kojiri; H Suda; M Yano
Journal:  Biochem Biophys Res Commun       Date:  1991-07-15       Impact factor: 3.575

2.  Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension.

Authors:  C Rubens; R Ewert; M Halank; R Wensel; H D Orzechowski; H P Schultheiss; G Hoeffken
Journal:  Chest       Date:  2001-11       Impact factor: 9.410

3.  Altered hemodynamics controls matrix metalloproteinase activity and tenascin-C expression in neonatal pig lung.

Authors:  Peter Lloyd Jones; Rene Chapados; H Scott Baldwin; Gary W Raff; Eugene V Vitvitsky; Thomas L Spray; J William Gaynor
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2002-01       Impact factor: 5.464

4.  Angiotensin-converting enzyme inhibition delays pulmonary vascular neointimal formation.

Authors:  K Okada; M L Bernstein; W Zhang; D P Schuster; M D Botney
Journal:  Am J Respir Crit Care Med       Date:  1998-09       Impact factor: 21.405

5.  Transgenic expression of the endothelin-B receptor prevents congenital intestinal aganglionosis in a rat model of Hirschsprung disease.

Authors:  C E Gariepy; S C Williams; J A Richardson; R E Hammer; M Yanagisawa
Journal:  J Clin Invest       Date:  1998-09-15       Impact factor: 14.808

6.  Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis.

Authors:  R M Tuder; M Chacon; L Alger; J Wang; L Taraseviciene-Stewart; Y Kasahara; C D Cool; A E Bishop; M Geraci; G L Semenza; M Yacoub; J M Polak; N F Voelkel
Journal:  J Pathol       Date:  2001-10       Impact factor: 7.996

7.  Endothelin B receptor deficiency predisposes to pulmonary edema formation via increased lung vascular endothelial cell growth factor expression.

Authors:  Todd Carpenter; Stacey Schomberg; Wolfgang Steudel; John Ozimek; Kelley Colvin; Kurt Stenmark; D Dunbar Ivy
Journal:  Circ Res       Date:  2003-08-14       Impact factor: 17.367

8.  Clearance of circulating endothelin-1 by ETB receptors in rats.

Authors:  T Fukuroda; T Fujikawa; S Ozaki; K Ishikawa; M Yano; M Nishikibe
Journal:  Biochem Biophys Res Commun       Date:  1994-03-30       Impact factor: 3.575

9.  Null mutation of endothelin receptor type B gene in spotting lethal rats causes aganglionic megacolon and white coat color.

Authors:  C E Gariepy; D T Cass; M Yanagisawa
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-23       Impact factor: 11.205

10.  Regulation of tenascin-C, a vascular smooth muscle cell survival factor that interacts with the alpha v beta 3 integrin to promote epidermal growth factor receptor phosphorylation and growth.

Authors:  P L Jones; J Crack; M Rabinovitch
Journal:  J Cell Biol       Date:  1997-10-06       Impact factor: 10.539

View more
  19 in total

1.  Idiopathic pulmonary arterial hypertension: an avian model for plexogenic arteriopathy and serotonergic vasoconstriction.

Authors:  Robert F Wideman; Krishna R Hamal
Journal:  J Pharmacol Toxicol Methods       Date:  2011-01-26       Impact factor: 1.950

2.  Improved pulmonary vascular reactivity and decreased hypertrophic remodeling during nonhypercapnic acidosis in experimental pulmonary hypertension.

Authors:  Helen Christou; Ossama M Reslan; Virak Mam; Alain F Tanbe; Sally H Vitali; Marlin Touma; Elena Arons; S Alex Mitsialis; Stella Kourembanas; Raouf A Khalil
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-01-27       Impact factor: 5.464

3.  Hemodynamic and histologic characterization of a swine (Sus scrofa domestica) model of chronic pulmonary arterial hypertension.

Authors:  Abraham Rothman; Robert G Wiencek; Stephanie Davidson; William N Evans; Humberto Restrepo; Valeri Sarukhanov; Amanda Rivera-Begeman; David Mann
Journal:  Comp Med       Date:  2011-06       Impact factor: 0.982

4.  Emergence of fibroblasts with a proinflammatory epigenetically altered phenotype in severe hypoxic pulmonary hypertension.

Authors:  Min Li; Suzette R Riddle; Maria G Frid; Karim C El Kasmi; Timothy A McKinsey; Ronald J Sokol; Derek Strassheim; Barbara Meyrick; Michael E Yeager; Amanda R Flockton; B Alexandre McKeon; Douglas D Lemon; Todd R Horn; Adil Anwar; Carlos Barajas; Kurt R Stenmark
Journal:  J Immunol       Date:  2011-08-03       Impact factor: 5.422

5.  The cancer paradigm of severe pulmonary arterial hypertension.

Authors:  Pradeep R Rai; Carlyne D Cool; Judy A C King; Troy Stevens; Nana Burns; Robert A Winn; Michael Kasper; Norbert F Voelkel
Journal:  Am J Respir Crit Care Med       Date:  2008-06-12       Impact factor: 21.405

6.  The xanthine derivative KMUP-1 inhibits models of pulmonary artery hypertension via increased NO and cGMP-dependent inhibition of RhoA/Rho kinase.

Authors:  Hui-Hsuan Chung; Zen-Kong Dai; Bin-Nan Wu; Jwu-Lai Yeh; Chee-Yin Chai; Koung-Shing Chu; Chung-Pin Liu; Ing-Jun Chen
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

Review 7.  Idiopathic pulmonary arterial hypertension.

Authors:  Amy L Firth; Jess Mandel; Jason X-J Yuan
Journal:  Dis Model Mech       Date:  2010 May-Jun       Impact factor: 5.758

Review 8.  Molecular pathogenesis and current pathology of pulmonary hypertension.

Authors:  Vinicio A de Jesus Perez
Journal:  Heart Fail Rev       Date:  2016-05       Impact factor: 4.214

9.  Interleukin-6 overexpression induces pulmonary hypertension.

Authors:  M Kathryn Steiner; Olga L Syrkina; Narasaish Kolliputi; Eugene J Mark; Charles A Hales; Aaron B Waxman
Journal:  Circ Res       Date:  2008-12-12       Impact factor: 17.367

10.  Erythropoietin upregulation in pulmonary arterial hypertension.

Authors:  Vanesa A Karamanian; Michael Harhay; Gregory R Grant; Harold I Palevsky; William E Grizzle; Roham T Zamanian; Kaori Ihida-Stansbury; Darren B Taichman; Steven M Kawut; Peter L Jones
Journal:  Pulm Circ       Date:  2014-06       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.